GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » Cyclically Adjusted PS Ratio

Avadel Pharmaceuticals (STU:AWK) Cyclically Adjusted PS Ratio : 5.35 (As of Jun. 07, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-06-07), Avadel Pharmaceuticals's current share price is €13.60. Avadel Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €2.54. Avadel Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 5.35.

The historical rank and industry rank for Avadel Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:AWK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.54   Med: 5.31   Max: 20.02
Current: 5.38

During the past years, Avadel Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 20.02. The lowest was 0.54. And the median was 5.31.

STU:AWK's Cyclically Adjusted PS Ratio is ranked worse than
82.64% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs STU:AWK: 5.38

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Avadel Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.273. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €2.54 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Avadel Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Avadel Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Avadel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.77 - - - 5.01

Avadel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.09 3.80 5.01 5.96

Competitive Comparison of Avadel Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avadel Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Avadel Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Avadel Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=13.60/2.54
=5.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avadel Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Avadel Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.273/120.9901*120.9901
=0.273

Current CPI (Mar. 2024) = 120.9901.

Avadel Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.083 100.773 0.100
201409 0.141 100.474 0.170
201412 -0.192 99.576 -0.233
201503 0.705 99.975 0.853
201506 1.073 100.573 1.291
201509 1.038 100.274 1.252
201512 0.768 99.676 0.932
201603 0.789 99.676 0.958
201606 0.839 101.072 1.004
201609 0.693 100.274 0.836
201612 0.990 99.676 1.202
201703 1.147 100.374 1.383
201706 0.970 100.673 1.166
201709 0.805 100.474 0.969
201712 0.725 100.075 0.877
201803 0.700 100.573 0.842
201806 0.680 101.072 0.814
201809 0.460 101.371 0.549
201812 0.496 100.773 0.596
201903 0.389 101.670 0.463
201906 0.416 102.168 0.493
201909 0.345 102.268 0.408
201912 0.264 102.068 0.313
202003 0.270 102.367 0.319
202006 0.128 101.769 0.152
202009 0.000 101.072 0.000
202012 0.000 101.072 0.000
202103 0.000 102.367 0.000
202106 0.000 103.364 0.000
202109 0.000 104.859 0.000
202112 0.000 106.653 0.000
202203 0.000 109.245 0.000
202206 0.000 112.779 0.000
202209 0.000 113.504 0.000
202212 0.000 115.436 0.000
202303 0.000 117.609 0.000
202306 0.018 119.662 0.018
202309 0.074 120.749 0.074
202312 0.198 120.749 0.198
202403 0.273 120.990 0.273

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Avadel Pharmaceuticals  (STU:AWK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Avadel Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avadel Pharmaceuticals (STU:AWK) Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.